Skip to main content

Dr. Robert Peter Gale and Eric Lax Help Demystify Radiation

By Eric McErlain
In the wake of the accident at Fukushima, the world once again got a chance to know Dr. Robert Peter Gale. One of the world's leading authorities on the biological effects of radaition, Dr. Gale first came to prominence in the late 1980s when he coordinated medical and relief efforts for victims of the accident at Chernobyl.

And in the wake of Fukushima, the world turned once again to Dr. Gale when it came to rationally gauging the immediate and long-term health effects of the accident in Japan. Perhaps we should be grateful then that Dr. Gale, along with co-author Eric Lax, has just written a new book aimed at demystifying radiation and its potential health effects. Radiation: What It Is. What You Need to Know, was just published by KnopfDoubleday and is available at Amazon.com and bookstores nationwide. Here's a thumbnail review that appeared earlier today in the New York Times:
Dr. Gale, a leukemia expert who advised governments in the wake of the nuclear disasters at Chernobyl in Ukraine and Fukushima in Japan takes a measured look at the health risks of radiation. He and Mr. Lax, a medical writer explain how mild doses of background radiation may be harmless, while extreme levels can cause cancer. In a twist, Dr. Gale reveals that most of the increase in our exposure in the last half century is not because of nuclear weapons or power but because of medical diagnostic tools like X-rays and CT scans.
Looks like I've got something new to download onto my Kindle.
Labels:

Comments

Post a Comment

Popular posts from this blog

Fluor Invests in NuScale

By
You know, it’s kind of sad that no one is willing to invest in nuclear energy anymore. Wait, what? NuScale Power celebrated the news of its company-saving $30 million investment from Fluor Corp. Thursday morning with a press conference in Washington, D.C. Fluor is a design, engineering and construction company involved with some 20 plants in the 70s and 80s, but it has not held interest in a nuclear energy company until now. Fluor, which has deep roots in the nuclear industry, is betting big on small-scale nuclear energy with its NuScale investment. "It's become a serious contender in the last decade or so," John Hopkins, [Fluor’s group president in charge of new ventures], said. And that brings us to NuScale, which had run into some dark days – maybe not as dark as, say, Solyndra, but dire enough : Earlier this year, the Securities Exchange Commission filed an action against NuScale's lead investor, The Michael Kenwood Group. The firm "misap...
1 comment
Read more

Wednesday Update

By
From NEI’s Japan micro-site: NRC, Industry Concur on Many Post-Fukushima Actions Industry/Regulatory/Political Issues • There is a “great deal of alignment” between the U.S. Nuclear Regulatory Commission and the industry on initial steps to take at America’s nuclear energy facilities in response to the nuclear accident in Japan, Charles Pardee, the chief operating officer of Exelon Generation Co., said at an agency briefing today. The briefing gave stakeholders an opportunity to discuss staff recommendations for near-term actions the agency may take at U.S. facilities. PowerPoint slides from the meeting are on the NRC website. • The International Atomic Energy Agency board has approved a plan that calls for inspectors to evaluate reactor safety at nuclear energy facilities every three years. Governments may opt out of having their country’s facilities inspected. Also approved were plans to maintain a rapid response team of experts ready to assist facility operators recoverin...
Post a Comment
Read more

Nuclear Utility Moves Up in Credit Ratings, Bank is "Comfortable with Nuclear Strategy"

By
Some positive signs that nuclear utilities can continue to receive positive ratings even while they finance new nuclear plants for the first time in decades: Wells Fargo upgrades SCANA to Outperform from Market Perform Wells analyst says, "YTD, SCG shares have underperformed the Regulated Electrics (total return +2% vs. +9%). Shares trade at 11.3X our 10E EPS, a modest discount to the peer group median of 11.8X. We view the valuation as attractive given a comparatively constructive regulatory environment and potential for above-average long-term EPS growth prospects ... Comfortable with Nuclear Strategy. SCG plans to participate in the development of two regulated nuclear units at a cost of $6.3B, raising legitimate concerns regarding financing and construction. We have carefully considered the risks and are comfortable with SCG’s strategy based on a highly constructive political & regulatory environment, manageable financing needs stretched out over 10 years, strong partners...
Post a Comment
Read more